Use of an automated pyrosequencing technique for confirmation of sickle cell disease

Camila Cruz de Martino, Cecilia Salete Alencar, Paula Loureiro, Anna Barbara de Freitas Carneiro-Proietti, Claudia de Alvarenga Máximo, Rosimere Afonso Mota, Daniela Oliveira Werneck Rodrigues, Nelson Gaburo Junior, Shannon Kelly, Ester Cerdeira Sabino, for the International Component of the NHLBI Recipient Epidemiology and Donor Evaluation Study (REDS-III)

1 Instituto de Medicina Tropical de São Paulo, Laboratório de Parasitologia, LIM 46, Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, Brazil, 2 Laboratório de Investigacao Medica, LIM 03, Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, Brazil, 3 Hemope, Recife, Pernambuco, Brazil, 4 Hemominas, Belo Horizonte, Minas Gerais, Brazil, 5 Hemorio, Rio de Janeiro, Rio de Janeiro, Brazil, 6 Hemominas, Montes Claros, Minas Gerais, Brazil, 7 Hemominas, Juiz de Fora, Minas Gerais, Brazil, 8 Vitalant Research Institute, San Francisco, California, United States of America, 9 UCSF Benioff Children’s Hospital Oakland, Oakland, California, United States of America

¶ Membership of the International Component of the NHLBI Recipient Epidemiology and Donor Evaluation Study (REDS-III) is provided in the Acknowledgments.

* sabinoec@gmail.com

Abstract

Background

The diagnosis of sickle cell disease (SCD) is made by hemoglobin assays such as high-performance liquid chromatography (HPLC), isoelectric focusing and cellulose acetate or citrate agar electrophoresis. These assays are easy to perform and used in large-scale newborn screening in many countries. These tests however may not easily differentiate Sβ0 thalassemia from SS or identify other hemoglobin variants, and in this case, hemoglobin (HBB) gene sequencing may be necessary.

Objectives

To develop a high throughput DNA based confirmatory assay for SCD and to detect mutations in the HBB gene

Methods

We developed an automated pyrosequencing technique (PyS) based on QIAGEN technology (Hilden, Germany) to detect homozygous or heterozygous hemoglobin S mutations as well as hemoglobin C mutations. The technique was tested on 2,748 samples from patients enrolled in a multi-center SCD cohort in Brazil. Patients were previously tested using HPLC to diagnose SCD as part of routine clinical care. Any subjects with discrepant results between HPLC and PyS or with heterozygous hemoglobin S detected had Sanger sequencing of the HBB gene.
Results
We identified 168 samples with discrepant results between HPLC and PyS and 100 with concordant PyS = heterozygous S and HPLC, which would suggest SB-thalassemia or other heterozygous S variants. The PyS assay correctly identified 1906 (98.7%) of the 1930 HbSS and 628 (98.7%) of the 636 HbSC samples. Of the 179 remaining samples, PyS correctly indicated S heterozygosis in 165 (92.2%). Of the 165 heterozygous S samples confirmed by Sanger as consistent with Sβ thalassemia genotype, 84 samples were classified as Sβ0 thalassemia and 81 as Sβ+ thalassemia. The most frequent beta thalassemia mutations of Sβ0 and Sβ+ were HBB: c.118C>T (Gln40Stop) and HBB c.92+6T>C, respectively.

Discussion
The PyS proved to be satisfactory for large-scale confirmatory testing of hemoglobin mutation. Moreover, with this study we were able to describe the most common β+ and β0 mutations in SCD patients with Sβ-thalassemia in a large multi-institutional SCD cohort in Brazil.

Introduction
Sickle cell disease (SCD) is an inherited red blood cell disorder in which at least one of the HBB genes has a Glu6Val mutation. When both genes are mutated (SS) the individual demonstrates a severe form of the disease typically called sickle cell anemia (SCA). The coinheritance of HbS with other abnormal β-globin chain variants can also cause SCD [1–3]. The most common mutations are sickle-hemoglobin C disease (HbSC) and sickle β-thalassemia (Sβ+ thalassemia and Sβ− thalassemia). Mutations designated as β0-thalassemia are associated with no normal hemoglobin A production, therefore clinical symptoms of Sβ0 thalassemia are typically as severe as SS and also usually classified as sickle cell anemia [4–6]. Mutations designated as β−thalassemia are associated with variable levels of normal hemoglobin A.

The diagnosis of SCD is made by hemoglobin assays such as high-performance liquid chromatography (HPLC), isoelectric focusing, cellulose acetate electrophoresis and citrate agar electrophoresis. Those assays are easy to perform and used in large scale newborn screening in many countries including Brazil. The tests however may not easily differentiate Sβ0 thalassemia from SS, and in this case HBB gene sequencing is necessary [7,8].

In 2013, a large multi-center cohort was established in Brazil to characterize clinical outcomes in the Brazilian SCD population under the National Heart Lung and Blood Institute Recipient Epidemiology and Donor Evaluation Study -III (REDS-III) program [9]. The genotype of the participants was defined by each site was based on HPLC measurement of variant hemoglobins, however the results were classified differently by each site. A genotype confirmation based on DNA was necessary to ensure standardized classification of SCD genotype for the research.

Because the HbS and HbC mutations are separated by only one nucleotide, it is not easy to develop specific probes for real time PCR [10,11]. We describe here a pyrosequencing technique (PyS) that was developed to confirm the SCD genotype for participants in the REDS-III Brazil SCD study. The technique was validated using Sanger sequencing of the HBB gene as the gold standard. This approach also allowed us to describe the most common HBB mutations in patients classified as Sβ0 thalassemia and Sβ+ thalassemia.
Materials and methods

Samples

This study was performed using samples collected for the REDS-III Brazil SCD cohort study (9) eligible participants were randomly selected that included institutions in four Brazilian states: São Paulo (Hospital das Clínicas), Minas Gerais (Hemominas), Rio de Janeiro (Hemorio) and Pernambuco (Hemope).

The study was approved by the local ethical review committee of participating institutions, namely, the Pro-Sangue foundation, Hemominas foundation, Hemope foundation and Hemorio blood bank. Also, the study was approved by the REDS-II collaborating centers (Blood Systems Research Institute/University of California at San Francisco, San Francisco, CA) and data-coordinating center (Westat, Inc.) in the United States.

The samples were collected in an EDTA tube, centrifuged at 3500rpm, and plasma was separated from cells. Both components were frozen and shipped to the central laboratory at the University of Sao Paulo for further testing.

DNA extraction was performed using the QIAasympohy apparatus (Qiagen, Germany) and the QIAasympohy DNA Mini Kit (Qiagen, Germany), following the manufacturer’s instructions and protocol.

Pyrosequencing

Primers sequences were designed using the Pyromark Assay by Design software as follows: Forward 5’ATTGCTTACATTTGCTTCTGACAC3’, Reverse 5’ACCAACTTCATCCACGTTCAC3’, targeting the same regions proposed by Sutton, Bouhassira [12]. PCR was performed with the PyroMark PCR Kit (QIAGEN) using 100 ng / μL of DNA according to the manufacturer’s protocol. The PCR product was used for the pyrosequencing assay with PyroMark Q24 Gold Kit (Qiagen, Germany) and subsequently subjected to PyroMark Q24 sequencer (Qiagen, Germany) using the primer sequence 5’CATGGTGCATCTGACT3’. The analysis was performed using Pyrogram (PQ24 Software) version 2.1 (Qiagen, Germany) as shown in Fig 1.

Sanger sequencing

We used the Sanger sequencing technique for the determination of β thalassemia mutations. PCR was used to amplify a fragment of 101 base pairs covering the coding region of the Beta
Globin gene, which has approximately 619 base pairs, using the follow primers sequence: (P1) 5’-TCCTAAGCCAGTGCCAGAAG-3’ and the downstream primer (P5) 5’-TCATTCGTCTGTTTCCCATTC3’ [13].

The purified PCR product was subjected to another PCR reaction using the ABI PRISM Big Dye Terminator Cycle Sequencing Ready Reaction kit (Applied Biosystems Foster City, CA) following the manufacturer’s protocol. Subsequently, the products of this reaction were analyzed by an ABI3500 automated sequencer (Applied Biosystems).

The sequences were edited through Sequencher Software (GENECODES) and the results were classified as $\beta^+$ or $\beta^0$ thalassemia mutations previously described in the literature through an online tool HbVarDatabase, Inc. (http://globin.bx.psu.edu/hbvar/) [14,15].

**TOPMed**

After establishment of the cohort, the REDS-III Brazilian SCD cohort was selected to participate in the National Heart Lung and Blood Institute Trans-Omics for Precision Medicine (TOPMed) Program, which generates whole-genome sequencing and other -omics data on well phenotyped cohorts. The program will integrate -omics data with molecular, behavioral, imaging, environmental, and clinical data to improve the prevention and treatment of blood and other disorders [16].

Whole genome sequencing was performed in samples of the REDS-III Brazilian SCD cohort by sequencing centers to a median depth of 39X using DNA from blood, PCR-free library construction and Illumina HiSeq X technology (nhlbiwgs.org). These sequences were utilized in the present research as a means of final confirmation of the SCD genotype in combination with Sanger sequences. Results of pyrosequencing assay were compared with final SCD genotype classification.

**Results**

The REDS-III Brazilian SCD cohort study enrolled 2,793 patients from 2013–2015. A total of 2,749 samples were obtained from the first visit of the enrolled patients. The number of patients per site classified by their original HPLC results is summarized in Table 1. The center from Rio de Janeiro (Hemorio) combined SS and S$\beta^0$ thalassemia in the same category, while the centers from Minas Gerais (Hemominas) combined S$\beta^0$ and S$\beta^+$. São Paulo and Pernambuco provided results that classified patients as SS, S$\beta^0$ and S$\beta^+$ separately.

|                  | Rio de Janeiro n (%) | São Paulo n (%) | Minas Gerais n (%) | Pernambuco n (%) | TOTAL   |
|------------------|----------------------|-----------------|--------------------|------------------|---------|
| HbSS            | 67 (72.0)            | 909 (64.9)      | 460 (85.3)         | 1436 (52.2)      |         |
| HbSC            | 112 (15.6)           | 15 (16.1)       | 452 (32.3)         | 46 (8.5)         | 625 (22.7)|
| HbS$\beta^0$    | 9 (9.7)              |                 | 10 (1.9)           | 19 (0.7)         |         |
| HbS$\beta^+$ or HbS$\beta^0$ | 39 (2.8)    |                 |                    | 39 (1.4)         |         |
| HbS$\beta^0$ or HbS$\beta$ | 567 (79.2) |                  |                    | 567 (20.6)       |         |
| HbS$\beta^+$   | 37 (5.2)             | 2 (2.2)         | 23 (4.3)           | 62 (2.3)         |         |
| Total           | 716                  | 93              | 1400               | 539              | 2748    |

HbSS: sickle cell anemia; HbSC: sickle-hemoglobin C disease; HbS$\beta^0$: $\beta$ thalassemia; S$\beta^+$ or S$\beta^0$: $\beta^+$ thalassemia or $\beta^0$ thalassemia; HbSS / HS$\beta^0$: sickle-cell disease or HbS$\beta^0$ thalassemia; HbS$\beta^+$: HbS$\beta^+$ thalassemia.

https://doi.org/10.1371/journal.pone.0216020.t001
All samples with a heterozygous S (n = 100) results or discrepant results between HPLC and PyS (n = 168) were submitted to Sanger sequencing of the HBB gene to assign a final genotype status. When TOPMed full genome sequencing of the cohort patients became available, we compared all the results. Twenty samples with discrepant results between REDS-III final classification and TOPMed classification were repeated using Sanger sequence and a final genotype was then assigned. Comparison of the PyS results with the final confirmed classification of SCD genotype is shown in Table 2. The PyS assay correctly identified 1906 (98.7%) of the 1930 HbSS and 628 (98.7) of the 636 HbSC samples. Of the 179 remaining samples, PyS correctly indicated S heterozygosis in 165 (92.2%).

Sanger sequencing allowed us to define the beta thalassemia mutations in the study population. The distribution of mutations varied according to the regions studied (Table 3). The most common mutation was a β0 mutation, HBB: c.118CT(Gln40Stop) [codon 39 (C>T)], in all sites with exception of Pernambuco, where the β+ mutation HBB:c.92+5G>C [IVS-1-5 (G>C)] was more common. In the state of Rio de Janeiro we identified one rare HBB mutation: HBB:c.75T>A [codon 24 (T>A)], a variant that leads to mild Sβ+ thalassemia.

An overall summary of the original classification made by HPLC at the participating sites, samples submitted to Sanger sequencing and final REDS-III SCD genotype classification considering our results compared to whole genome sequencing generated by TOPMed is shown in Fig 1.

**Table 2. Comparison of Pyrosequencing results with final SCD classification, REDS-III Brazil SCD cohort study.**

| Final SCD Classification | HbSS | HbSC | HbS| TOTAL |
|-------------------------|------|------|----|-------|
| HbSS                    | 1903 | 12   | 15 | 1930  |
| HbSC                    | 8    | 628  |    | 636   |
| HbSβ+                   | 9    | 72   |    | 81    |
| HbSβ0                   | 4    | 80   |    | 84    |
| HbSD                    | 1    | 6    |    | 7     |
| HbS/HPFH                | 3    |      |    | 3     |
| HbS|                |      |      |    | 2     |
| S/Quebec-Chori          | 1    |      |    | 1     |
| S/K-Woolwich            | 1    |      |    | 1     |
| S/Korle-Bu              | 1    |      |    | 1     |
| S/Porto Alegre          | 1    |      |    | 1     |
| S/Deer Lodge            | 1    |      |    | 1     |
| TOTAL                   | 1934 | 640  | 180| 2748  |

HbSS: homozygous hemoglobin S sickle cell disease; HbSC: sickle-hemoglobin C disease; HbSβ0: sickle-β0 thalassemia; Sβ+: sickle-β + thalassemia; Hb S: heterozygous S HPFH: hereditary persistence of fetal hemoglobin; Samples correctly identified by pyrosequencing are shown in bold

https://doi.org/10.1371/journal.pone.0216020.t002

**Discussion**

There is a need for rapid and precise methods to facilitate the diagnosis of hemoglobinopathies, especially in situations in which conventional testing may not be possible or reliable. For example only frozen samples, in which hemoglobin based assays are less reliable, were available for this research study. The ability to differentiate SS from Sβ0 thalassemia is also not always possible using hemoglobin based assays as nearly all hemoglobin detected is hemoglobin S with no hemoglobin A present. In the absence of information regarding hemoglobin mutations in parents or other clinical and laboratory testing, DNA based testing is required to
confirm the SCD genotype. However, the vast majority of cases would be expected to be homozygous SS and sequencing a large number of samples to separate the two would be labor intensive and cost prohibitive. Pyrosequencing is relatively quick and simple and also allows a large scale approach to provide timely diagnosis. In the present study we used the pyrosequencing technique to classify the hemoglobinopathy diagnosis of participants in a large multi-institutional cohort study of SCD by confirming HbSS, HbSC and heterozygous S participants. This allowed targeted Sanger sequencing only in participants with results not concordant with clinical diagnosis assigned at treating center (n = 165) and in heterozygous S samples (n = 100) for identification of hemoglobin mutations. The pyrosequencing assay correctly identified 2,699 (98.2%) of the samples and proved to be a satisfactory technique for large-scale testing.

The pyrosequencing technique is a highly reliable tool for the determination of small regions inside the globin genes, and has the advantage of being a relatively simple technique. In addition, pyrosequencing is faster and is associated with a lower cost of operation when compared to other sequencing methodologies[17]. There were 49 samples misclassified by PyS, mostly due to the low level of the pyrogram peaks, which could be improved by standardizing the peak levels below which the batch should be repeated.

In this study we also described the most common β+ and β0 thalassemia mutations among Sβ thalassemia cohort participants in four states of Brazil. Of the heterozygous S samples confirmed by Sanger, 84 were classified as Sβ0 thalassemia and 81 as Sβ+ thalassemia.

The types of beta thalassemia mutations demonstrated in this cohort reflect the genetic diversity of the study population. The Brazilian population is the result of admixture between different groups at different time periods; the colonizing Spaniards mixed with the indigenous

| Mutations                      | B-Thal. | MG | PE | RJ | SP | n (%) |
|--------------------------------|---------|----|----|----|----|------|
| HBB:c.118C>T[Gln40Stop](codon 39 (C>T)] | SB0     | 26(38.8) | 6(14.0) | 10(23.3) | 5(41.7) | 47 (28.5) |
| HBB:c.92+6T>C [IVS-1-6 (T>C)]      | SB+     | 6(8.9) | 10(23.3) | 7(16.3) | 2(16.7) | 25 (15.2) |
| HBB:c.92+1G>A [IVS-I-1 (G>A)]     | SB0     | 11(16.4) | 4(9.3) | 5(11.6) | 1(8.3) | 21 (12.7) |
| HBB:c.93-21G>A [IVS-I-110 (G>A)]  | SB+     | 7(10.4) | 3(7.0) | 5(11.6) | 2(16.7) | 17 (10.3) |
| HBB:c.92+5G>C [IVS-I-5 (G>C)]    | SB+     | 1(1.5) | 11(25.6) | 2(4.7) | 1(8.3) | 15 (9.1) |
| HBB:c.-79A>G(C-29AG) [-29A>G]     | SB+     | 3(4.5) | 6(14) | 9 (5.5) |
| HBB:c.92+5G>A [IVS-I-5 (G>A)]   | SB+     | 2(3.0) | 1(2.3) | 3(7) | 7 (4.2) |
| HBB:c.315+1G>A [IVS-II-1 (G>A)] | SB0     | 4(6.0) | 2(4.6) | 6 (3.6) |
| Hz IVS-II-849 (A>G)               | SB0     | 1(1.5) | 2(4.6) | 3 (1.8) |
| Hz PolyA, AATAAAA>AACAAA          | SB+     | 2(3.0) | 2 (1.2) |
| Hz-88 (C>T)                      | SB+     | 2(4.6) | 2 (1.2) |
| HBB:c.–138C>T                    | SB+     | 1(2.3) | 1 (0.6) |
| Hz IVSII-839(T>C) Hz IVSII-844 (C>A) | SB+ | 1(2.3) | 1 (0.6) |
| DELEÇÃO 572het DelG               | SB0     | 1(1.5) | 1 (0.6) |
| HBB:c.321_322insG Hz Cod 106/107(+G) | SB0 | 1(2.3) | 1 (0.6) |
| Hz IVSII-849 (A>G)               | SB0     | 1(1.5) | 1 (0.6) |
| Hz IVSII-839(T>C) Hz IVSII-844 (C>A) | SB+ | 1(2.3) | 1 (0.6) |
| DELEÇÃO 572het DelG               | SB0     | 1(1.5) | 1 (0.6) |
| Hz IVSII-849 (A>G)               | SB0     | 1(1.5) | 1 (0.6) |
| Hz IVSII-839(T>C) Hz IVSII-844 (C>A) | SB+ | 1(2.3) | 1 (0.6) |
| p.Glu7Glyfs                      | SB0     | 1(2.3) | 1 (0.6) |
| Hz IVSII-849 (A>G)               | SB0     | 1(1.5) | 1 (2.3) | 2 (1.8) |
| TOTAL                           | 67      | 43 | 43 | 12 | 165 |

* No DNA available for further sequences
populations as well as with African slaves during three centuries. Later, immigration from Spain, Italy, Portugal contributed further to the admixture of the present-day Brazilians [18].

The most frequent mutation in our subjects, HBB:c.118C>T(Gln40Stop) Codon 39 (C>T), is also the most prevalent Sβ thalassemia mutation in the Mediterranean. It is believed that codon 39 (C>T) is of Roman origin, and has a high prevalence in Sardinia, mainland Italy, Spain, Portugal and Tunisia [19]. Different studies also found this mutation to be frequent in Venezuela [18], Northern Greece [20], Syria [21], and confirmed it in Tunisia [22] and Italy [23].

The next most common β0 thalassemia mutation in our cohort, IVS-I-1, shows a restricted geographical distribution in Eastern Mediterranean countries (Syria, Lebanon, Jordan, Palestine and Egypt) [21].

The presence of the IVS-I-6 mutation, the most common β+ mutation in our cohort, appears to be a contribution from the Portuguese to the genetic makeup of the population, as it corresponds to 29.4% of the alleles in β+ mutations in Portugal [18,24].

Our results are in accordance with previous Brazilian studies [24–27]. As expected, considering the migratory activity of the Brazilian population and ethnic ancestry, the pattern observed is similar to the Mediterranean populations. Interestingly, a study identifying mutations in 31 Sβ thalassemia patients in the state of Rio Grande do Norte did not identify the mutation Codon 39 (C>T) that was common in our study and others in Brazil [28]. They identified 15 (48.4%) patients with the IVS-I-1 mutation, 13 (41.9%) with the IVS-I-6 mutation, 2 (6.5%) with the IVS-I-110 mutation and 1 (3.2%) with IVS-I-5 mutation.

Different from the other states in our study, the most common mutation in the state of Pernambuco was IVS-I-5 (G>C). This mutation is very common in Asia, especially in Malaysia and Indonesia and in several regions of India [29]. In studies conducted by Khan et al. from 2011–2013 in four provinces of Pakistan, the most frequent mutation detected in a total of 63 samples of β-thalassemia was IVS-I-5(G>C) (33.9%) [30]. In India, more than 90% of mutations in beta thalassemia involve IVS1-5 (G>C) [31,32]. Similar to our findings, studies by Silva and Araujo [33,34] also identified this mutation in the population of Recife, Pernambuco. In the 17th century Recife was an important commercial harbor, it is possible that people from the Indian subcontinent (Goa) were brought as slaves by the Portuguese to that area [34].

The racial heterogeneity of the immigrant population in a non-endemic country significantly increases the spectrum of hemoglobinopathy mutations and their combinations found in individuals, making the provision of a molecular diagnostic prenatal diagnosis service more challenging. With the testing algorithm described, it was possible to determine the spectrum of Sβ thalassemia mutations and their combinations in a Brazilian SCD population. It is important to determine the correct mutations for genetic counseling and to identify patients potentially eligible for new drugs or gene therapy trials that may be available for targeted populations [35].

In conclusion, the pyrosequencing technique is a highly reliable tool for the classification of SCD and is suitable for large-scale testing to identify hemoglobin S (homozygous or heterozygous carriers) and C mutations. This allows targeted hemoglobin sequencing in a limited number of patients, facilitating proper diagnosis when conventional techniques may have limited ability and ensuring proper hemoglobinopathy diagnosis which is essential for correct screening and treatment strategies for patients with SCD.

**Acknowledgments**

The authors acknowledge all of the research staff at the participating blood centers in Brazil who have enrolled patients into the study and completed all study procedures. At each site the
following specific people are recognized for their commitment and contribution to this project: Fundação Pró-Sangue (São Paulo)–Alfredo Mendrone Jr., Cesar de Almeida Neto; ITACI–Instituto de Tratamento do Câncer Infantil (São Paulo)–Roberta Carlucci, Erivanda Bezerra; Hemominas–Belo Horizonte (Minas Gerais)–Carolina Miranda, Tassila Salomon, Franciane Mendes de Oliveira, Valquiria Reis, Nayara Duarte, Barbara Malta; Hemominas–Juiz de Fora (Minas Gerais)–Daniela Werneck; Hemominas; Montes Claros (Minas Gerais)–Rosimere Mota, José Wilson Sales, Maria Aparecida Souza, Rodrigo Ferreira; Fundação Hemope–Recife (Pernambuco)–Maria do Carmo Valgueir; Regina Gomes, Airly Goes Maciel, Rebeca Talamatu Dantas; Hemorio–(Rio de Janeiro)–Flavia Herculano, Ana Claudia Pereira, Ana Carla Alvarenga, Adriana Grilo, Fabiana Canedo; Instituto de Matemática e Estatística da Universidade de São Paulo—USP (São Paulo)–Marcio Moikawa, Mina Cintho Ozahata, Rodrigo Muller de Carvalho, João Eduardo Ferreira. US Investigators: RTI–Research Triangle Institute, International–Christopher McClure; National Institutes of Health, National Heart, Lung, and Blood Institute–Simone A. Glynn.

Author Contributions
Conceptualization: Camila Cruz de Martino, Cecilia Salete Alencar, Ester Cerdeira Sabino.
Data curation: Camila Cruz de Martino, Cecilia Salete Alencar, Ester Cerdeira Sabino.
Formal analysis: Camila Cruz de Martino, Cecilia Salete Alencar.
Funding acquisition: Nelson Gaburo Junior, Ester Cerdeira Sabino.
Investigation: Camila Cruz de Martino, Cecilia Salete Alencar, Shannon Kelly, Ester Cerdeira Sabino.
Methodology: Camila Cruz de Martino, Cecilia Salete Alencar, Shannon Kelly, Ester Cerdeira Sabino.
Project administration: Ester Cerdeira Sabino.
Resources: Camila Cruz de Martino, Cecilia Salete Alencar, Ester Cerdeira Sabino.
Software: Camila Cruz de Martino, Cecilia Salete Alencar.
Supervision: Cecilia Salete Alencar, Ester Cerdeira Sabino.
Validation: Camila Cruz de Martino, Cecilia Salete Alencar.
Visualization: Camila Cruz de Martino, Cecilia Salete Alencar.
Writing – original draft: Camila Cruz de Martino, Cecilia Salete Alencar, Anna Barbara de Freitas Carneiro-Proietti, Shannon Kelly, Ester Cerdeira Sabino.
Writing – review & editing: Camila Cruz de Martino, Paula Loureiro, Anna Barbara de Freitas Carneiro-Proietti, Claudia de Alvarenga Máximo, Rosimere Afonso Mota, Daniela Oliveira Werneck Rodrigues, Nelson Gaburo Junior, Shannon Kelly, Ester Cerdeira Sabino.

References
1. Kawar N, Alrayyes S, Compton A-A, Aljawari H, Baghdan D, Yang B, et al. Sickle cell disease; An overview of the disease and its systemic effects. Dis Mon. 2018; 0(0):1–7.
2. Soares LF, Lima EM, Silva JA da, Fernandes SS, Silva KM da C, Lins SP, et al. Prevalência de hemoglobinas variantes em comunidades quilombolas no estado do Piauí, Brasil. Cien Saude Colet. 2017; 22(11):3773–80. https://doi.org/10.1590/1413-812320172211.04392016 PMID: 29211162
21. Murad H, Moassas F, Jarjour R, Mukhalala Y, Al-Achkar W. Prenatal molecular diagnosis of Kalleas C, Anagnostopoulos K, Sinopoulou K, Delaki E, Margaritis D, Bourikas G, et al. Phenotype and hematological em uma coorte neonatal com hemoglobina SC. J Pediatr (Rio J). 2018; 4(1):22.

22. Ronaghi M. Pyrosequencing Sheds Light on DNA Sequencing. Genome. 2018; 11:3–11.

23. Ouali F, Siala H, Bibi A, Hadj Fredj S, Dakhlaoui B, Othmani R, et al. Prenatal diagnosis of hemoglobin-

24. Rocha LB da SM, Freitas M. Distribuição das mutações da β-thalassemia em Fortaleza, Ceará. J Bras Patol Med Lab. 2010; 46(6):437–41.
25. Fernandes AC, Azevedo Shimmoto MM, Furuzawa GK, Vicari P, Figueiredo MS. Molecular analysis of 
β-thalassemia patients: First identification of mutations HBB:c.93-2A>G and HBB:c.114G>A in Brazil. 
Hemoglobin. 2011; 35(4):358–66. https://doi.org/10.3109/03630269.2011.588354 PMID: 21797703
26. Reichert VCD, Castro SM, Wagner SC, Albuquerque DM, Hutz MH, Leistner-Segal S. Identification of 
β-thalassemia mutations in South Brazilians. Ann Hematol. 2008; 87(5):381–4. https://doi.org/10.1007/
s00277-007-0418-z PMID: 18071703
27. Carrocini GCS, Venancio LPR, Pessoa VLR, Lobo CLC, Bonini-Domingos CR. Mutational Profile of 
Homozygous β-Thalassemia in Rio de Janeiro, Brazil. Hemoglobin. 2017; 41(1):12–5. https://doi.org/
10.1080/03630269.2017.1289958 PMID: 28366028
28. Cabral CHK, Serafim ESS, de Medeiros WRDB, de Medeiros Fernandes TAA, Kimura EM, Costa FF, 
et al. Determination of β haplotypes in patients with sickle-cell anemia in the state of Rio Grande do 
Norte, Brazil. Genet Mol Biol. 2011; 34(3):421–4. https://doi.org/10.1590/S1415-47572011005000027 
PMID: 21931513
29. Silveira ZML, Barbosa M das V, Fernandes TAA de M, Kimura EM, Costa FF, Sonati M de F, et al. 
Characterization of beta-thalassemia mutations in patients from the state of Rio Grande do Norte, Bra-
zil. Genet Mol Biol. 2011; 34(3):425–8. https://doi.org/10.1590/S1415-47572011005000032 PMID: 
21931514
30. Khan J, Ahmad N, Siraj S, Hoti N. Genetic determinants of β-thalassemia intermedia in Pakistan. 
Hemoglobin. 2015; 39(2):95–101. https://doi.org/10.3109/03630269.2014.1002136 PMID: 25707679
31. Warghade S, Britto J, Haryan R, Dalvi T, Bendre R, Chheda P, et al. Prevalence of hemoglobin variants 
and hemoglobinopathies using cation-exchange high-performance liquid chromatography in central 
reference laboratory of India: A report of 65779 cases. J Lab Physicians. 2018; 10(1):73–9. https://doi.org/
10.4103/JLP.JLP_57_17 PMID: 29403210
32. Patel AP, Patel RB, Patel SA, Vaniawala SN, Patel DS, Shrivastava NS, et al. β-thalassemia mutations 
in Western India: Outcome of prenatal diagnosis in a hemoglobinopathies project. Hemoglobin. 2014; 
38(5):329–34. https://doi.org/10.3109/03630269.2014.951889 PMID: 25222044
33. Silva FR. O Trafico de Escravos para O Portugal Setecenti sta: Uma Visão A Partir do “Despacho dos 
Negros Da India, De Cache o e de Angola” Na casa da India de Lisboa. Revista de Historia. 2013;47– 
73.
34. Araújo AS, Silva WA, Leão SAC, Bandeira FCGM, Petrou M, Modell B, et al. A Different Molecular Pat-
tern of β-Thalassemia Mutations in Northeast Brazil. Hemoglobin. 2003; 27(4):211–7. https://doi.org/
10.1081/hem-120026045 PMID: 14649311
35. Uludağ A, Uysal A, Uludağ A, Ertekin YH, Tekin M, Kütkü B, et al. Prevalence and mutations of β-thalas-
sema trait and abnormal hemoglobins in premarital screening in Çanakkale province, Turkey. Balk J 
Med Genet. 2016; 19(1):29–34.